Literature DB >> 10450513

Mechanisms of central and peripheral T-cell tolerance: lessons from experimental models of multiple sclerosis.

S Anderton1, C Burkhart, B Metzler, D Wraith.   

Abstract

Studies of experimental autoimmune encephalomyelitis in conventional and transgenic mouse models have clarified mechanisms of central and peripheral tolerance to myelin antigens. It is now clear that myelin antigens are expressed in the thymus and their expression can influence generation of the potential autoimmune T-cell repertoire. How autoreactive T cells escape tolerance in the thymus is largely unclear. One mechanism has been revealed through the use of a transgenic mouse expressing a T-cell receptor specific for a myelin antigen. T cells specific for the N-terminal epitope of myelin basic protein escape tolerance through low avidity interaction. The affinity of antigen binding to MHC also proves to be important for induction of peripheral tolerance. Peptides may be administered in solution to adults in order to reinstate peripheral tolerance and suppress disease. Induction of antigen-specific suppression with synthetic peptides can result in either linked or bystander suppression and this appears to involve the generation of T cells secreting suppressive cytokines. The use of altered peptide ligands for induction of peripheral tolerance has been investigated. This can be achieved but the complexity of the approach argues against its use for treatment of human autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10450513     DOI: 10.1111/j.1600-065x.1999.tb01311.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  12 in total

Review 1.  Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities.

Authors:  S M Anderton
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

Review 2.  Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?

Authors:  M Peakman; C M Dayan
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

Review 3.  Challenges to achieving clinical transplantation tolerance.

Authors:  A D Salama; G Remuzzi; W E Harmon; M H Sayegh
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 4.  Is the CD200/CD200 receptor interaction more than just a myeloid cell inhibitory signal?

Authors:  Konstantinos Minas; Janet Liversidge
Journal:  Crit Rev Immunol       Date:  2006       Impact factor: 2.214

5.  Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones.

Authors:  M Tommasi; D Castelletti; M Pasti; G Fracasso; I Lorenzetti; S Sartoris; C Pera; G B Ferrara; G Tridente; M Colombatti
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

6.  Primary biliary cirrhosis: seeking the silent partner of autoimmunity.

Authors:  I Sutton; J Neuberger
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

7.  Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease.

Authors:  M Stanford; T Whittall; L A Bergmeier; M Lindblad; S Lundin; T Shinnick; Y Mizushima; J Holmgren; T Lehner
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

8.  CD4+CD25+ regulatory T cells limit the risk of autoimmune disease arising from T cell receptor crossreactivity.

Authors:  Leigh A Stephens; David Gray; Stephen M Anderton
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-15       Impact factor: 11.205

9.  TCR affinity for self-ligands influences the development and function of encephalitogenic T cells.

Authors:  Jianwei Li; Omar Vandal; Derek B Sant'Angelo
Journal:  PLoS One       Date:  2011-03-17       Impact factor: 3.240

10.  Successful immunotherapy with matrix metalloproteinase-derived peptides in adjuvant arthritis depends on the timing of peptide administration.

Authors:  Jolanda H M van Bilsen; Josée P A Wagenaar-Hilbers; Maarten J F van der Cammen; Mariska E A van Dijk; Willem van Eden; Marca H M Wauben
Journal:  Arthritis Res       Date:  2002-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.